Kotak Healthcare IDCW Reinvest Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹100

Kotak Healthcare IDCW Reinvest Direct Plan

NAV
₹14.6810
+0.46%
(2 Jan)
AUM
419 Cr
TER
0.74%
Risk
Very High Risk
Insights
Total Expense Ratio (TER) is in the bottom 25% of comparable funds
Net Asset Value (NAV) is above its 200 days moving average
In beta. Send feedback here.
Compare with other fund
1Y
+41.1%
+27.9%
+25.6%
+25.6%
+25.6%
3Y
NA
+35.1%
+37.0%
+37.0%
+37.0%
5Y
NA
+28.0%
+25.1%
+25.1%
+25.1%
ALL
+43.5%
+17.2%
+12.3%
+12.3%
+12.3%
VOL
13.1%
20.0%
20.3%
20.3%
20.3%
TER
0.7%
0.8%
0.7%
0.7%
0.7%
AUM
₹419 Cr
₹1,345 Cr
₹4,686 Cr
₹4,686 Cr
₹4,686 Cr
INFO
3.31
0.86
0.61
0.61
0.61
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
Kotak Healthcare IDCW Reinvest (DR)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 30th Nov
Top holdings
Sun Pharmaceuticals Industries Ltd
15.0%
Cipla Ltd
6.8%
Divi's Laboratories Ltd
5.3%
Innova Captab Ltd
4.3%
Jubilant Pharmova Ltd
4.1%
Orchid Pharma Ltd
4.0%
J.B. Chemicals & Pharmaceuticals Ltd
3.9%
Apollo Hospitals Enterprise Ltd
3.9%
Max Healthcare Institute Ltd Ordinary Shares
3.9%
Torrent Pharmaceuticals Ltd
3.9%
Top industry exposure
Healthcare
96.8%
Basic Materials
2.3%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹100
Additional lumpsum
₹100
Portfolio turnover
35%
Lock-in period
-
Exit load
• 1% for redemption within 30 days
Fund objective
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly Pharma, Healthcare, and allied sectors. However, there is no assurance that the objective of the scheme will be achieved .
Fund manager(s)
Abhishek Bisen
Shibani Kurian
Dhananjay Tikariha

FAQs